Valneva gets approval for Chikungunya vaccine in Canada
Valneva announces Health Canada approval of the world’s first chikungunya vaccine, IXCHIQ®.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2171 entries already.
Entries by Thomas Gabrielczyk
Tubulis from Munich doses first Patient with own ADC linker technology
Tubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models.
BIOSECURE Act could affect half of US biopharmaceutical development
The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical trials (phases I to III) and a third are in early preclinical and discovery stages, according to GlobalData, the analytics company.
Danone, Michelin and DMC Biotechnologies open new cooperative fermentation site
French dairy giant Danone, engineering materials group Michelin, US start-up DMC Biotechnologies and Crédit Agricole Centre France have joined forces to create the Biotech Open Platform as precision fermentation centre.
Researchers identify blockers of CNS effects of PD1 cancer therapy
German researchers have tracked down the causes for central nervous system side effects of cancer immunotherapies and blocked them in small animal models.
The Power of 4P Medicine in Revolutionizing Patient Care
In the rapidly evolving healthcare landscape, the concept of 4P Medicine—Prevention, Prediction, Precision, and Participation—marks a transformative shift towards personalized healthcare. This approach, refined over the last 15 years, aims to revolutionize how we understand, prevent, and treat diseases by focusing on each patient’s unique needs. The recent whitepaper by Worldwide Clinical Trials highlights the profound impact of 4P Medicine on clinical development and patient care.
CATALYSER – the Start-up-Magazine 2/24
A print magazine focussing on start-ups in the life sciences! Like a catalyst, it aims to promote young companies in the life sciences with the right impulses.
Evotec SE cashes in €20m milestone
Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).
Tacalyx’ extends seed capital financing
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
CRISPR screen highlights genes behind T cell plasticity in autoimmunity
Researchers at University Hospital Hamburg-Eppendorf have laid the foundation to screen for molecules that shift Th17 cells from proinflammatory or immune-dampening mode.